Kiniksa Pharmaceuticals International (KNSA) Intangibles (2021 - 2026)

Kiniksa Pharmaceuticals International's Intangibles history runs 6 years deep, the most recent figure standing at $15.0 million for Q1 2026.

• Quarterly Intangibles fell 6.25% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (down 6.25% YoY) and the FY2025 annual result came in at $15.2 million, down 6.15% from the prior year.
• Intangibles was $15.0 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $15.2 million in the prior quarter.
• Across five years, Intangibles topped out at $20.0 million in Q2 2022 and bottomed at $15.0 million in Q1 2026.
• A 5-year average of $17.5 million and a median of $17.0 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2023 — Intangibles increased 5.26% — and 2024, when it fell 18.75%.
• Kiniksa Pharmaceuticals International's Intangibles stood at $20.0 million in 2022, then changed by 0.0% to $20.0 million in 2023, then decreased by 18.75% to $16.2 million in 2024, then dropped by 6.15% to $15.2 million in 2025, then slipped by 1.64% to $15.0 million in 2026.
• Business Quant data shows KNSA's Intangibles at $15.0 million in Q1 2026, $15.2 million in Q4 2025, and $15.5 million in Q3 2025.